Lansing, MINCT07218432Now EnrollingIRB Ready

Breast Cancer Stage I Clinical Trial in Lansing, MI

Access cutting-edge breast cancer stage i treatment through this clinical trial at a research site in Lansing. Study-provided care at no cost to qualified participants.

Sponsored by Barbara Ann Karmanos Cancer Institute

Quick Self-Assessment

See if you qualify for this Lansing location

Preparing your pre-screening questions…

Expert Care in Lansing

Access breast cancer stage i specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer stage i treatment provided free

Apply for This Lansing Location

Check if you qualify for this breast cancer stage i clinical trial in Lansing, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lansing

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lansing site if eligible
  4. 4Begin participation

About This Breast Cancer Stage I Study in Lansing

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.

Sponsor: Barbara Ann Karmanos Cancer Institute

Who Can Participate

Inclusion Criteria

Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative according to the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (ER and/or PR (progesterone receptor) \>1% and HER2 negative by immunohistochemistry \[IHC\] and/or fluorescent in situ hybridization \[FISH\]).
Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery.
Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection
Participant must have archival tissue available.
Participant must be a woman aged 22 years or older
Participant must be able to understand a written informed consent document and be willing to sign it
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session

Exclusion Criteria

Participants that are receiving or will receive neoadjuvant chemotherapy or neoadjuvant hormonal therapy
Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
Participants that are taking any other investigational drugs
Participants that are pregnant or breastfeeding due to the unknown but potential risk for adverse events. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued
Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).
Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.
Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device
Participants with a known severe (e.g., anaphylactic) allergy to nickel.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lansing?

Yes, this clinical trial (NCT07218432) has an active research site in Lansing, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Stage I Treatment Options in Lansing, MI

If you're searching for breast cancer stage i treatment options in Lansing, MI, this clinical trial (NCT07218432) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lansing research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer stage i specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer stage i clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Lansing, MI

See all breast cancer clinical trials recruiting in Lansing — not just this study.

Browse Breast Cancer Trials in Lansing →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Lansing?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lansing, MI